Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Advocacy: Past Wins, Future Outlook

Angus Worthing, MD, FACP, FACR  |  January 18, 2018

ACR President David Daikh, MD, PhD, and American Academy of Ophthalmology President Cynthia Bradford, MD, published a strong opinion piece in the influential beltway publication, The Hill, last month. We helped organize a broad coalition of physician societies and patient groups to fight this. We have also been engaged in a series of meetings with key Congressional offices, and it’s critical they hear your voice, too. Tell your elected officials to protect access to Part B therapies (currently the second advocacy campaign in the ACR’s Legislative Action Center). Patients and families of Medicare beneficiaries can send a letter. Do it now!

Medicare Rehabilitation Therapy Caps
Our Medicare patients who need physical, occupational and speech therapy face self-rationing due to the $2,010/year hard cap that was instituted on Jan. 1. Soon, patients will start hitting that cap and will not be able to receive more rehab benefits in 2018 without paying out of pocket. Luckily, with key Congressional committees supporting active legislation that permanently repeals the therapy cap, there’s momentum right now. Thirty groups, including the ACR, are campaigning to #StopTheCap by Jan. 19. Tell lawmakers: Therapy Can’t Wait! Patients and families can also send emails.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Regulations
As the Trump administration works to reduce and simplify regulation across agencies, the ACR advocated for continuing the FDA’s critical scientific vigilance in developing a biosimilars marketplace. Specifically, the ACR’s wish list for the FDA regarding biosimilars includes finalizing the robust plan to require three-switch studies for biosimilars to be designated as interchangeable, and creating memorable, distinct names for biosimilars (in the form of memorable suffixes). It is quite unfortunate that despite the approval of biosimilars in the U.S., prices are being kept high and competition is being held back by dealings between pharmaceutical companies and intermediaries in the drug distribution system, like PBMs. The ACR, through ATAP, is working to fix that.

Cognitive Codes
Frustrated by documentation? Confused about whether to bill a level 3 or 4? The ACR continued its work this fall to create a new set of billing codes that recognize cognitive work, instead of emphasizing procedures as the current evaluation and management (E/M) codes do. Your team, together with a coalition of cognitive specialties, met with Congressional offices and policymakers at the CMS to communicate the importance of new codes in our efforts to both incentivize physicians to go into cognitive specialties and also to more easily take part in value-based payment models, which are not set up for cognitive work. Stay tuned!

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Legislation & AdvocacyPractice SupportProfessional Topics Tagged with:2017 ACR/ARHP Annual MeetingAngus Worthingdrug costsWashington D.C. update

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    High Cost of Specialty Drugs Demands Action

    July 6, 2021

    Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences